Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

MEK/RAF molecular glue IK-595

An orally bioavailable mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK)/RAF molecular glue and dual kinase inhibitor, with potential antineoplastic activity. Upon oral administration, MEK/RAF molecular glue IK-595 targets and glues B-RAF and C-RAF protein kinases with MEK, forming stable and inactive MEK-RAF complexes. This prevents RAF-dependent phosphorylation and activation of MEK, inhibits the activity of MEK, thereby preventing the activation of MEK-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. In addition, this inhibits the anti-apoptotic activity of C-RAF, which may also inhibit tumor cell proliferation. Oncogenic mutations in RAF plays a key role in the overactivation of the RAS-mitogen-activated protein kinase (MAPK) pathway and drives tumor cell proliferation and survival. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types. CRAF-mediated reactivation of MEK and MAPK signaling leads to resistance to MEK inhibitors. IK-595 is able to cross the blood-brain barrier (BBB).
Synonym:MEK-RAF complex inhibitor IK-595
MEK/RAF inhibitor IK-595
Code name:IK 595
IK-595
IK595
Search NCI's Drug Dictionary